ALT
ALT
Positions held
Your positionsALT isn't in your positions.
Add it to see shares, cost, and P&L here.
Fundamentals
| Market cap | — | Enterprise value | — | Trailing P/E | — | Forward P/E | — |
| PEG | — | Price / book | — | Beta | — | Dividend yield | — |
| Revenue growth | — | Earnings growth | — | Gross margin | — | Operating margin | — |
| Profit margin | — | ROE | — | ROA | — | Debt / equity | — |
| Current ratio | — | Free cash flow | — | Analyst recommendation | — | Mean target | — |
| 52w high | — | 52w low | — |
Quarterly
No data yet.
Yearly (6y)
No data yet.
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-07 · Can NVO's Semaglutide Push Create Growth Beyond Cardiometabolic Care?
2026-10-01 · Altimmune Details Pemvidutide’s Path Toward a Liver-Disease Franchise
2026-09-23 · Altimmune to Participate in Stifel Cardiometabolic Forum
2026-09-22 · VKTX, GPCR, ALT Stocks Rise: Novo Nordisk Signals Bigger M&A As It Chases Over 5 ‘Multi-Blockbusters’
2026-09-11 · Why Is Altimmune (ALT) Up 14.2% Since Last Earnings Report?
2026-09-08 · Altimmune’s (ALT) Three Liver Trials Move Forward At Once
2026-09-03 · Altimmune to Participate in the Wells Fargo 21st Annual Healthcare Conference
2026-08-19 · Is Altimmune Worth Buying as Cash Rises but Execution Risks Linger?
2026-08-19 · Altimmune's Phase III MASH Study Puts 2029 Data in Investor Focus
2026-08-14 · Kodiak's Q2 Loss Wider Than Expected, Pipeline Development in Focus
2026-08-13 · ALT's Q2 Loss Narrower Than Expected, Pemvidutide's Studies in Focus
2026-08-12 · Altimmune Inc (ALT) (Q2 2026) Earnings Call Highlights: Advancing MASH and AUD Pipelines with ...
Price (daily)
Full chart · RSI · MACD · patterns